PhaseBio Pharmaceuticals Inc
phasebio.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2022 10-Q, filed Aug 12, 2022. Its latest SEC filing is a 15-12G from Sep 30, 2024.
10-Q for Q2 FY2022, filed Aug 12, 2022
The sections below describe the company as of the FY2021 annual report.
How Did They Make Money?
Under the bentracimab sublicense, the company receives an upfront payment, payments when development or regulatory milestones are met, and payments and royalties tied to product sales. Government grants support specific research projects.
10-K for FY2021, filed Mar 24, 2022Sublicense revenue relates to the revenue we recognized in relation to the Alfasigma Sublicense, which contains multiple components…View ↗
Grant revenue is derived from government grants that support our efforts on specific research projects. We recognize grant revenue when…View ↗
In June 2021, we entered into a sublicense agreement with Alfasigma, or the Alfasigma Sublicense, pursuant to which we granted Alfasigma…View ↗
$10.8M
-
10-K for FY2021, filed Mar 25, 2022
$10.8M ↗
Who Were Their Customers?
Alfasigma has exclusive rights to distribute and sell bentracimab in Europe and specified nearby markets. PhaseBio planned to market it independently in the United States if approved.
10-K for FY2021, filed Mar 24, 2022
Did Revenues Turn Into Profits?
No. It lost $131.1M in FY2021.
10-K for FY2021, filed Mar 25, 2022
−$107.4MView ↗
10-K for FY2021, filed Mar 25, 2022
−$131.1MView ↗
10-K for FY2021, filed Mar 25, 2022
−$50.1MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q2 FY2022, filed Aug 12, 2022
−$16.7MView ↗
- ▼ −42% (Loss)
- vs −$28.7M in Q2 FY2021
-
Jul 12, 2024
Court confirms plan to liquidate remaining assets and wind down operations
The plan projects no recovery for equity holders.
Sources
8-K, filed Jul 12, 2024
On June 26, 2024, the Bankruptcy Court entered an order approving the Plan on a final basis and confirming the Plan. A summary of certain…View ↗
Regional commercialization rights
The earlier report described worldwide commercial rights and possible partnerships outside the United States; the latest gives Alfasigma exclusive rights to distribute and sell bentracimab in Europe and specified nearby markets.
10-K for FY2018, filed Mar 26, 2019 10-K for FY2021, filed Mar 24, 2022Commercialize our product candidates. We have entered into exclusive license agreements with AstraZeneca for PB2452 and Duke University for…View ↗
In June 2021, we entered into a sublicense agreement with Alfasigma, or the Alfasigma Sublicense, pursuant to which we granted Alfasigma…View ↗
Therapy focus
The older report described an orphan-disease focus and a candidate for pulmonary arterial hypertension; the latest describes cardiovascular therapies and a candidate for treatment-resistant hypertension.
10-K for FY2018, filed Mar 26, 2019 10-K for FY2021, filed Mar 24, 2022We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan…View ↗
Loading...
